https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/1 2026-08-09T00:44:29Z https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/4410 Journal Title: Real-world outcomes in patients with hormone receptor positive, human epidermal growth factor receptor 2 receptor-negative advanced breast cancer and visceral metastases at baseline – advanced hormone receptor positive breast cancer registry in Australia Authors: Wigston, Lucas; Morris, Ali; Wen Lok, Sheau; Baron-Hay, Sally; de Boer, Richard; Boyle, Frances; Collins, Ian M.; Cuff, Katharine; Gately, Lucy; Georgiou, Chloe; Greenberg, Sally; Karki, Bhaskar; Mok, Kelly; Morton, Catherine; Nottage, Michelle; Rainey, Natalie; Torres, Javier; Tung, Iris; Wong, Vanessa; Jude, Evon; Gibbs, Peter; Nott, Louise Abstract: Background Hormone receptor-positive, HER2− breast cancer (HR+/HER2−) represents most advanced breast cancer (ABC) cases. Patients with visceral metastases are considered to have aggressive disease, historically treated with first-line chemotherapy (CT). However, trials (RIGHT Choice, PADMA, ABIGAIL) have demonstrated that cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) provide superior efficacy and tolerability in this setting. Aims To compare outcomes between first-line CDK4/6i + ET and CT in Australian patients with HR+/HER2− ABC and visceral metastases. Methods Data were obtained from the ARORA registry, a prospective observational study capturing real-world outcomes for Australian patients with HR+/HER2− ABC. Eligible patients were aged ≥18 years, with visceral metastases diagnosed after 1 January 2020, and received first-line systemic therapy. Participants were stratified by initial treatment: CT, ET + CDK4/6i or ET monotherapy. ET monotherapy was analysed as a separate cohort and excluded from comparative progression-free survival (PFS) and overall survival (OS) analyses. Primary endpoints were (1) OS: time from metastatic diagnosis to death and (2) PFS: time to progression on first-line therapy. Results A total of 418 patients were included, with a median age of 56 years and median follow-up of 12 months. The majority of patients (73.7%) received first-line CDK4/6i + ET. Compared with CT, CDK4/6i + ET yielded significantly longer PFS (20.0 vs 11.9 months, P = 0.0006). A trend towards improved OS was observed (28.6 vs 22.9 months, P = 0.1399). Conclusion This real-world analysis reinforces CDK4/6i + ET as the preferred first-line treatment for HR+/HER2− ABC with visceral metastases. While selection bias cannot be excluded, these findings support the shift away from routine first-line CT. Ongoing follow-up will clarify the OS impact. 2026-07-30T00:00:00Z https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/4408 Journal Title: Rapidly changing landscape of diabetic kidney disease management: recent advances and the road ahead Authors: Sherng Young Wang, Samuel; Zhi Chan, Yan; Ran Luo, Xiao; Yue Ting Tan, Nichole; Klein, Martin; Javaid, Muhammad M. Abstract: Diabetic kidney disease (DKD) management has advanced rapidly in recent years, with new therapies supplementing established treatments. The cardiorenal benefits of sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA) and nonsteroidal mineralocorticoid receptor antagonists (ns-MRA) in patients with DKD have been proven in several large randomised controlled trials. Recent studies show that combining SGLT2i, ns-MRA and renin–angiotensin–aldosterone system (RAAS) blockade significantly slows DKD progression compared with using single agents. The concurrent use of four agents, including GLP-1RA, SGLT2i, ns-MRA and RAAS blockade, may confer additional benefits, and a four-pillar approach to managing DKD could become standard therapy in the future. Additional investigational agents, including endothelin receptor antagonists, aldosterone synthesis inhibitors, and Janus kinase 1 and Janus kinase 2 inhibitors, have demonstrated encouraging results in Phase 2 trials. These therapies may offer further treatment options for patients who are unable to use other agents. 2026-07-23T00:00:00Z https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/4409 Journal Title: Salvage therapies for recurrent grade 4 IDH-wildtype glioma: a BRAIN Registry analysis of real-world treatment patterns Authors: Sanderson, Emma; Drummond, Katharine; Dowling, Anthony; Bennett, Iwan; Freilich, Ronnie; Phillips, Claire; Ahern, Elizabeth; Campbell, David; Campbell, Robert; Harrup, Rosemary; Reeves, Simone; Collins, Ian; Jennens, Ross; Joshi, Sachin; Gan, Hui; Fay, Michael; Lynam, James; Lim, Lisi Elizabeth; Rosenthal, Mark; Dumas, Megan; Gibbs, Peter; Gately, Lucy Abstract: Purpose The prognosis for patients with glioblastoma after failure of first-line therapy is poor. Despite this, the standard of care for patients with recurrent disease is not well-defined. Here we report on the use of salvage therapies in glioblastoma using real-world data. Methods Data were extracted from the BRAIN Registry for patients diagnosed with glioblastoma (Grade 4, IDH wild-type) between 09/2019 and 01/2024. Only patients who received salvage therapies following a documented date of recurrence/progression were included. Relevant descriptive and intergroup statistics were used, with survival calculated using Kaplan-Meier and Cox regression used for multivariate analyses. Results 275 patients were identified. Median age was 61 (range:23–88) years, with 56% being ECOG 0–1 at recurrence. Median time to progression was 7.6 months with 65% recurring/progressing during first-line therapy. Systemic therapy (85%) was most utilised with 67% receiving single-agent bevacizumab. Outcomes in this subgroup were similar to clinical trial data. 29% patients underwent re-resection with 58% of these then receiving systemic treatment. Compared with no surgery, patients who underwent re-resection were younger (p = 0.02), of better performance status (p = 0.006) and more likely to have recurred post completing first-line therapy (p = 0.001). Few patients (n = 9) received re-irradiation with median of 15 months between radiation events. Median post-progression survival (PPS) was 9.5 months. After adjustment for confounders, there was no difference in PPS for patients who underwent re-resection versus systemic therapy alone (p = 0.242). The survival differences observed between treatment modalities likely reflect patient factors influencing treatment selection and were impacted by small subgroup sizes. Conclusion Systemic therapy is most utilised in the salvage setting, predominantly bevacizumab. Certain patient characteristics were associated with re-resection. Re-irradiation was rarely used. 2026-07-23T00:00:00Z https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/4406 Journal Title: Employers’ perceptions of supporting an employee’s work reintegration following stroke Authors: Walsh, Hannah; Lannin, Natasha; Barclay, Linda; Smith, Madeleine J.; O'Keefe, Sophie Abstract: Purpose: A significant proportion of stroke survivors are of working age. While employers play a pivotal role in facilitating work reintegration, their perspectives remain unknown. This study aimed to explore employers' experiences and perspectives on supporting their employees in returning to work after stroke. Methods: Qualitative descriptive approach. Participants were employers of stroke survivors who had received vocational rehabilitation, and were known to receive support from the clinical team. Semi-structured interviews were conducted online and data were examined using reflexive thematic analysis. Results: Ten employers were interviewed. Four themes emerged: (1) The vocational rehabilitation team (subtheme: Working as a team); (2) Knowledge is key; (3) Employers' involvement in facilitating return-to-work (subtheme: The employee-employer relationship); and (4) Impact of workplace culture, policies and workload management on return-to-work. Employers highlighted structured plans and supportive workplace culture as key facilitators of reintegration. They valued collaboration between the employee, occupational therapist and workplace; however, most wanted more information about stroke-related impairments to provide tailored support. Conclusion: Employer insights underscore the importance of collaborative vocational rehabilitation involving healthcare professionals and workplaces. Findings deepen understanding of employer perspectives and highlight the need for specialist resources and communication to strengthen employer capacity in supporting employees after stroke. 2026-06-15T00:00:00Z